These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 38456971)

  • 1. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2293-2307. PubMed ID: 38456971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of an artificial intelligence-based tool in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 4. Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Pellegrino S; Catalano L; Pane F; Del Vecchio S; Pace L
    Ann Hematol; 2020 Jan; 99(1):127-135. PubMed ID: 31776725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
    J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Total Lesion Glycolysis by
    McDonald JE; Kessler MM; Gardner MW; Buros AF; Ntambi JA; Waheed S; van Rhee F; Zangari M; Heuck CJ; Petty N; Schinke C; Thanendrarajan S; Mitchell A; Hoering A; Barlogie B; Morgan GJ; Davies FE
    Clin Cancer Res; 2017 Apr; 23(8):1981-1987. PubMed ID: 27698001
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma.
    Goksel S; Ilkkilic K; Bulbul O; Akdogan E
    Nucl Med Commun; 2022 Oct; 43(10):1077-1083. PubMed ID: 36006402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can physiologic colonic [
    Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice.
    Terao T; Machida Y; Tsushima T; Miura D; Narita K; Kitadate A; Takeuchi M; Matsue K
    Br J Haematol; 2020 Oct; 191(2):223-230. PubMed ID: 32253760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW; Lee KY; Kim HJ; Kim WS; So Y
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.